A Prospective, Randomized, Partially Double-blinded, Placebo and Active-controlled, Parallel, Multiple-dose, Matched-pairs, Single-center Phase 2 Clinical Trial to Explore Efficacy and Safety of Topical Application of EG-Decorin to Skin Graft Donor Site in Patients with Wound
Latest Information Update: 20 Mar 2019
At a glance
- Drugs EGT 022 (Primary)
- Indications Wounds
- Focus Therapeutic Use
- Acronyms EG-Decorin_SKGRFT_P2P
- Sponsors EyeGene
Most Recent Events
- 20 Mar 2019 New trial record